Agent for treating hepto.biliary diseases
Patent 5739161 Issued on April 14, 1998. Estimated Expiration Date: 
February 12, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 12, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References16-Substituted prostaglandins Liver cytoprotection using PGE's Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds Prostaglandins E and anti-ulcers containing same Prostaglandins E and anti ulcers containing same Patent #: 5284858 InventorApplicationNo. 797940 filed on 02/12/1997US Classes:514/530, Z contains a cyclopentyl or cyclopentene ring514/573, Cyclopentyl or cyclopentene (e.g., prostaglandins, etc.)560/121, Cyclopentyl in acid moiety (e.g., prostaglandins, etc.)562/503Cyclopentyl (e.g., prostoglandins, etc.)ExaminersPrimary: Gerstl, RobertAttorney, Agent or FirmForeign Patent References
International ClassesA61K 031/557C07C 415/00 Foreign Application Priority Data1994-06-03 JPAbstractThe object of the present invention is to provide a pharmaceutical composition for treatment of hepato.biliary disease reduced in side effect such as diarrhea, which comprises 16,16-difluoro-15-keto-PGs having at least one methyl group or ethyl group on the carbon atom at the 17- or 18-position or adjacent to the terminal methyl group of ω-chain as an essential component. |
| ||||||||||||||
